Dabigatran indications and usage: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Argatroban}} {{CMG}}; {{AE}} {{SS}} ==Indications and Usage== PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvul..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Dabigatran}} | ||
{{CMG}}; {{AE}} {{SS}} | {{CMG}}; {{AE}} {{SS}} | ||
Revision as of 15:10, 31 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Indications and Usage
PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.[1]
References
- ↑ "ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC]". Retrieved 31 January 2014.